Theravance files ampreloxitine investor presentation based on post hoc CYPRESS analysis

Theravance Biopharma filed an investor presentation based on post hoc analyses of its Phase 3 CYPRESS study for ampreloxetine, highlighting challenges with the primary efficacy data and aiming to reshape the FDA's regulatory review for multiple system atrophy treatment.

This Wire brief sits within Fusion42's coverage of Biotech.